Biotech Alert: Searches spiking for these stocks today

Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Aurinia Pharmaceuticals (AUPH), 2,165% surge in interest
• Redhill Biopharma (RDHL), 1,156% surge in interest
• Savara (SVRA), 597% surge in interest
• Gamida (GMDA), 573% surge in interest
• Idera Pharmaceuticals (IDRA), 436% surge in interest

Pipeline and key clinical candidates for these companies:

Aurinia Pharmaceuticals is focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the company introduced Lupkynis, which it notes is the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis.

RedHill Biopharma is primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers’ diarrhea in adults. RedHill’s key clinical late-stage development programs include: RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria disease; opaganib, or ABC294640, a first-in-class oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for hospitalized COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-107, or upamostat, an oral serine protease inhibitor in a Phase 3-stage study as treatment for non-hospitalized symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; and RHB-102 , with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D.

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Its lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP. 

Gamida Cell is at work on an immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources, including umbilical cord blood-derived cells and NK cells, to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies.

Idera is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. Its portfolio includes late-stage programs that we are developing to be innovative therapeutics capable of addressing the unmet medical needs of these individuals.

Recent news on these stocks:

January 3

Aurinia Pharmaceuticals announced it has entered into a settlement agreement with Sun Pharmaceutical Industries, Sun Pharmaceuticals Industries and Sun Pharma Global FZE that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review, or IPR, directed at Aurinia’s U.S. Patent No. 10,286,036, as well as settlement of the ongoing patent infringement litigation in the United States related to Sun’s Cequa product. Under the settlement agreement, which is contingent upon the U.S. Patent Trial and Appeal Board approving the joint motion to terminate the IPR, both parties agreed to dismiss their claims and counterclaims against each other and cease bringing any future further action against the other.

RedHill Biopharma announced publication of positive data from a Phase 2 study of once-daily oral investigational RHB-107 in non-hospitalized symptomatic COVID-19 patients, in the peer-reviewed International Journal of Infectious Diseases. The study showed that RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and 100% reduction in hospitalization due to COVID-19.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.

Keywords: biotech, biotech sector, biotech alert, investingchannel, XBI, SPDR S&P Biotech ETF